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Abstract 
The majority of lymphoblastic (precursor cell) neoplasms present as leukemias. 
Consequently, the guidelines for lineage determination and subtyping of precursor cell 
neoplasms were primarily established for flow cytometry methods. Large scale studies of 
non-leukemic lymphoblastic lymphomas are lacking so far. We analyzed a large series of 
pediatric lymphoblastic lymphoma patients treated within a prospective randomized trial. (the 
Euro-LB 02 study). Among 193 lymphomas, in which a detailed immunohistochemical 
analysis was performed, there were several unusual and diagnostically challenging 
morphological and immunophenotypical variants. These included 11 lymphomas with mixed 
phenotypes expressing markers of at least two hematopoietic lineages, 7 TdT negative 
lymphoblastic lymphomas and 3 undifferentiated hematopoetic neoplasms that could not be 
assigned to any lineage with certainty. Our data indicate that WHO guidelines for lineage 
determination and subtyping of precursor cell leukemia need to be adapted before they can 
be applied to immunohistochemical diagnosis of lymphoma. Using the experience from this 
cohort we suggest a resource-saving diagnostic staining panel for the immunohistochemical 
analysis of precursor cell neoplasms in formalin-fixed paraffin-embedded tissue. 
 
 2
Introduction 
 
Lymphoblastic (precursor) lymphoma is the second most common type of non-Hodgkin 
lymphoma in children and adolescents in Western Europe 6 and derives from immature 
precursor lymphoblasts whose differentiation is arrested at early stages of maturation. 
Treatment trials in children and adolescents subdivide lymphoblastic neoplasms into two 
diseases:  acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) 19. There 
is an ongoing discussion as to whether LBL and ALL are two distinct entities or whether they 
represent two variants of one and the same disease and the distinction is arbitrary 6. The 
extent of blast infiltration of the bone marrow is currently used to distinguish between the two 
diseases, with 25% of tumor cells in the smears as an arbitrarily chosen cut-off 26. LBL 
frequently presents as a mediastinal tumor in patients who are often critically ill but have little 
or no bone marrow infiltration 19. Thus, diagnostic material obtained in cases of LBL is often 
limited to small specimens. Consequently, most of our knowledge about lymphoblastic 
neoplasms derives from cases of ALL and the number of studies on LBL is limited 6, 8, 11, 16-18, 
22 . This situation is reflected in the WHO2008 classification, which refines the diagnostic 
criteria for precursor cell neoplasms in a way that  might pose a problem for pathologists who 
have to deal with tissue biopsy specimens without access to multicolor flow cytometry (FC) 
26.  
 
This study represents the largest published series of LBL cases characterized by 
immunophenotyping. All samples were obtained during a prospectively randomized clinical 
trial for children and young adults under the age of 21 (the Euro-LB 02 study). The analysis 
was conducted on formalin-fixed paraffin-embedded material (FFPE) and its purpose was to 
define the immunophenotype of LBL in children. The diagnostic staining approach for LBL 
recommended here was developed for use on FFPE specimens and for widespread 
application, including general pathology laboratories, and is intended as a step-wise and 
material-sparing diagnostic process. Thus, this is not a competing but a complementary 
concept to that of the WHO.  
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Material and Methods 
 
Patients and materials: 
The patient cohort was recruited in a prospective randomized trial, the Euro-LB 02 study 
(“Euro-LB 02 treatment protocol for lymphoblastic lymphomas of the European Intergroup 
Cooperation on Childhood Non-Hodgkin Lymphoma (EICNHL) International Multicentre 
Therapy Study Group”), which included patients suffering from lymphoblastic lymphoma 
(LBL) who were 21 years and younger. According to current criteria, LBL patients had less 
that 25% blasts in the bone marrow smears. 
 
During the time of recruitment (2002 – 2008) patients were registered by 8 participating study 
groups in 14 European countries. All cases, in which the initial diagnosis was made on tissue 
biopsy specimens (n=279) were identified by the international data base at the NHL-BFM 
study center in Giessen, Germany. Of these the national reference pathologists were able to 
collect 196 for review. In 83 patients no reference pathology review was possible because 
the diagnosis had been based on liquid material rather than a tissue biopsy (n=8), because 
of a lack of access to the biopsy material for central review (n=70) or insufficient material for 
appropriate review (n= 5).  
 
Pathology review and immunophenotype 
Selected cases were reviewed by the panel of national reference pathologists at a 
multiheaded microscope, including all challenging cases (TdT-negative, ambiguous lineage, 
unusual morphology, staining difficult to interpret, low quality specimen). In addition, 
randomly chosen cases from every participating study group were reviewed to ensure that 
the quality of the immunohistochemical staining and interpretation adhered to the defined 
standards.  
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All immunohistochemical (IHC) stainings were performed on whole tissue sections except for 
a few supplemental stains that were performed centrally on tissue microarrays (n=55, n=3 
and n=54 for Pax5, CD1a and CD19,  respectively). The scoring procedure was agreed upon 
at a consensus meeting and all the stainings were scored semiquantitatively by individual 
reference pathologists as negative, weak (<30% positive tumor cells or all tumor cells weakly 
positive), positive (>30% positive tumor cells) or not interpretable. The staining panel 
included CD20, CD79a, Pax5, CD19, CD10, IgM, CD3, CD1a, CD4, CD8, CD5, CD2 MPO, 
TdT, and CD34. Due to the retrospective nature of the study, the staining procedures and 
antibody sources for these markers varied between the participating countries and over time. 
Since biopsy material obtained from the mediastinal tumors was often limited, the number of 
performed immunohistochemical stainings also varied from case to case.  
 
A T-cell lineage was established on the basis of CD3 expression, a B-cell lineage by the 
expression of at least two of the following B-cell markers, CD19, CD79a, Pax5 and/or CD20, 
and a myeloid lineage by expression of MPO. Mixed lineage acute leukemia (MPAL) was 
diagnosed if the tumor cells fulfilled the diagnostic criteria for two lineages (figure 4). In 
accordance with the WHO classification, “bi-lineal” and “bi-phenotypical” diseases were not 
distinguished. Undifferentiated hematopoietic neoplasm (UHN) was diagnosed if a lineage 
could not be determined according to the above mentioned criteria and after exclusion of 
other non-hematopoietic small round cell tumors. 
 
Statistical analysis 
Fisher’s exact test was performed using GraphPad Prism software. 
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Results 
 
Diagnosis 
Since the clinical analysis of the Euro-LB 02 trial is not as yet available this study focuses on 
the pathology review. The clinical results will be published elsewhere. Overall data for 196 
study patients were collected and reviewed by the panel. In eight of the registered patients 
the panel excluded the diagnosis of precursor cell lymphoma (3 diffuse large B-cell 
lymphomas, 1 Burkitt lymphoma, 2 mature aggressive B-cell lymphomas, and 2 
unclassifiable lymphomas due to insufficient immunostains and these cases were excluded 
from all further analysis. In the remaining cohort (n=188), the diagnostic categories of the 
WHO classification for precursor cell neoplasms were used (Swerdlow et al., 2008). The vast 
majority of LBL displayed a typical morphology with monomorphic sheets of medium-sized 
blasts with round nuclei, finely dispersed nuclear chromatin and a narrow rim of cytoplasm. 
However, in a small subset of cases (n=3) we observed considerable morphological variation 
(figure 1).  
 
In 146 cases all stainings required for application of the criteria outlined in the Material and 
Methods section were evaluated. Of those 42 (29%) were classified as precursor B-cell 
lymphoblastic lymphoma (B-LBL), 90 (62%) as precursor T-cell lymphoblastic lymphoma (T-
LBL), 11 (7%) as MPAL and 3 (2%) as UHN. A subset of confirmed precursor lymphomas 
(n= 42) displayed markers of at least one lineage (36% B, 64% T), but the IHC panel was not 
complete to exclude any additional  lineage differentiation. 
 
 
T-cell lymphoblastic lymphoma (T-LBL) 
Within the group of 90 T-LBL, we initially attempted to distinguish the immunological 
maturation stages: pro-T-LBL, pre-T-LBL, cortical T-LBL and medullary/mature T-LBL as 
defined by the EGIL classification 2. To apply this classification it is necessary to distinguish 
between cytoplasmic and membranous CD3 staining for differentiation of  early pro- and pre-
T-LBL  and  medullary/mature T-LBL. However, the panel agreed that a distinction between 
cytoplasmic and membranous CD3 staining can not be reliably made using IHC on FFPE 
specimens (figure 2). Thus, we could only distinguish 49 cortical T-LBL (54%), which differed 
from all other subtypes in their expression of CD1a, and noncortical (n=35, 39%) or 
unclassifiable T-LBL that lacked sufficient IHC stainings  for subtyping (n=6, 7%). This 
percentage of cortical LBL in our study was comparable to previous publications 6. 
 
In order to evaluate whether additional IHC stainings might help to distinguish early T-LBL 
(pro- and pre-T-LBL) from later T-LBL (cortical and medullary/mature T-LBL) we assessed 
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possible markers of early stages of T-cell differentiation (CD34, CD10, CD4/CD8 double 
negative) in cortical and noncortical T-LBL. CD34 and CD10 were expressed in a 
comparable fractions of cases in both the cortical and noncortical subtypes (12% versus 
23%, p=0.3386 and 67% versus 56%, p=0.5314, respectively, Table 1). Cases expressing 
either CD4 or CD8 (single positive) were significantly more frequent in the group of 
noncortical T-LBL (42%) than in the group of cortical T-LBL (18%, p=0.0354). As expected, 
cortical T-LBL were more often double positive for CD4 and CD8 than noncortical T-LBL 
(78% versus 36%, p=0.0003) and showed a lower frequency of double negativity (4% versus 
23%, p=0.284) (table 1).  
 
B-cell lymphoblastic lymphoma (B-LBL) 
Subtyping of B-LBL was performed according to the well established categories of CD10-
/IgM- pro-B-LBL (0/42, 0%), CD10+/IgM- common-B-LBL (20/42, 46%) and CD10+/IgM+ pre-
B-LBL (5/42, 12%) 2. Lymphomas, in which the B-cell nature was established but that lacked 
the necessary data for subtyping were categorized as not otherwise specified (nos). Within 
the group of B-LBL nos (n=17, 41%), 15 (36%) were CD10 positive and either common- or 
pre-B-LBL, but lacked reliable IgM staining. When only the 25 B-LBL with complete subtyping 
were considered, there was no difference in the subtype distribution in our series as 
compared with a previously published large series of precursor pB-ALL (data not shown) 21.  
 
The majority of B-LBL were positive for CD79a. However, since CD79a might be expressed 
in a considerable number of T-LBL and in accordance with the criteria of the WHO 
classification, we required a second positive B-cell marker in order to prove B-cell lineage 
differentiation., Also we determined the sensitivity and the specificity of B-cell markers in B-
LBL. 12% of T-LBL samples (3/47, cortical and 6/33, noncortical, Table 2) were positive for 
CD79a, but none for any of the other B-cell markers (CD20, CD19 and Pax5). It should be 
noted that in CD79a positive T-LBL we also observed CD10 expression in 4/6 cases. 
Whereas the sensitivity of CD20 for the detection of the B-cell lineage in pLBL is poor (12/35, 
34% positive), the marker Pax5, was highly sensitive, with 35/35 (100%) of the analyzed B-
LBL cases being positive.  
 
Mixed lineage acute leukemia/lymphoma (MPAL) 
The group of MPAL consisted of 7 lymphomas with myeloid and B-cell lineage markers, 2 
with myeloid and T-cell lineage and 2 with B-cell and T-cell lineage (table 3, figure 3). All 
MPAL were positive for TdT but they expressed CD34 in only 5 of 10 cases that could be 
evaluated. All T-lineage MPAL were negative for CD1a (0/4) and CD56 (0/4).  
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Undifferentiated hematological neoplasia (UHN) 
Three cases were classified as UHN because they lacked any lineage specific markers but 
expressed markers of immature hematopoetic cells such as TdT (1/3) or CD34 (2/3). 
Furthermore, less specific hematopoietic markers were detected (table 4) and other small 
round cell tumors were excluded, e.g. by staining for CD56 (0/3, data not shown). Cases 
number 1 and 3 presented as localized bone tumors in the lumbar spine and the iliac bone, 
respectively, whereas case number 2 presented as a mediastinal tumor. Case number 3 was 
initially misdiagnosed as Ewing sarcoma because of its strong CD99 positivity in the absence 
of other main lineage markers and its suggestive localization within the bone. 
 
TdT negative LBL 
Terminal deoxynucleotide transferase (TdT), the major marker of a precursor cell neoplasm 
in the B- and T-cell lineage, was expressed in 166/173 (96%) of precursor cell neoplasms. 
Seven LBL were diagnosed as TdT negative LBL, but all of these lymphomas displayed the 
typical morphology of LBL in addition to the immunophenotypic features of precursor cell 
neoplasms, such as weak or partial expression of TdT in 1-5% of the lymphoma cells (4/7), 
expression of CD34 (1/7), coexpression of CD3 and CD79a (1/7), or coexpression of CD4 
and CD8 (1/7).   
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Discussion 
 
The new WHO lymphoma classification published in 2008 25 introduced several important 
changes in the field of B- and T-precursor cell neoplasms: (i) the marker definition for 
determining the cell lineage was changed and the EGIL scoring system for biphenotypic 
leukemia 2 was abandoned, (ii) the terminology and definition of mixed phenotype precursor 
cell neoplasms was established and (iii) subtypes defined by recurrent genetic aberrations 
were introduced. Most of our knowledge on the immunophenotypes of precursor cell 
neoplasms has been gathered from cases of leukemic disease by means of FC. Several of 
the current diagnostic criteria are difficult to apply on tissue specimens. The advantage of our 
study is that it points out the specific problems associated with the diagnosis of precursor cell 
neoplasms by means of histology and IHC on FFPE material. Biopsy material and 
consequently the number of feasible immunostains are often limited due to localization of the 
tumors. Therefore we propose a well reflected algorithm (figure 5) applicable for diagnosing 
and subtyping LBLs in daily practice.Using this algorithm, we identified T-LBL twice as often 
as B-LBL, which confirms previous reports 6.  
 
The diagnosis of LBL should combine (i) typical morphology, (ii) proof of precursor cell 
immunophenotype, (iii) precise lineage definition and (vi) subtyping by additional stainings 
and/or genetic analysis to obtain a final diagnosis. In our data TdT expression is the most 
useful tool for confirming the precursor cell nature of a lymphoma. It should be used to stain 
all cases of LBL as well as other blastic neoplasms in children, since morphological variants 
of LBL may mimic other aggressive lymphomas, such as diffuse large B-cell lymphomas 
(figure 1). Moreover, this staining can be helpful in the differential diagnosis of immature 
hematological neoplasms versus other small round blue cell tumors, but it should be noted 
that rare nonhematopoietic tumors such as Merkel cell carcinomas may also express TdT 3, 5, 
24 . In addition TdT-positive bone marrow hematogones have to be considered when judging 
trephine specimens 12. Similarly TdT-positive cortical thymocytes of normal thymus should 
not be mistaken for T-LBL in small mediastinal biopsies. IHC staining for cytokeratin can be 
of help in such situations. In the rare cases of TdT negative LBL with otherwise typical 
lymphoblastic morphology, either expression of CD1a or CD34, coexpression of CD79a and 
CD3 or coexpression of CD4 and CD8 can be used to identify the precursor cell nature of the 
lymphoma. Coexpression of CD4 and CD8 has also been reported in cases of mature T-
NHL, such as T-cell prolymphocytic leukemia and adult T-cell leukemia/lymphoma 26. 
However these entities are usually not a differential diagnosis in children.  
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Immunohistochemical stainings for CD3 and myeloperoxidase (MPO) are powerful tools for 
identifying the T-cell and myeloid lineage with a single staining for each lineage, according to 
the requirements of the WHO 2008 classification (figure 4). Proof of the B-cell lineage 
requires at least two B-cell markers to be positive. We chose CD79a staining as primary 
screening marker for two reasons. First, this is a widely known pan-B-cell marker that is 
accepted by the WHO and is also available in general pathology laboratories for rapid initial 
diagnosis in clinically urgent situations. Second, it is - as we showed in our series - a highly 
sensitive marker for detecting B-cell differentiation in LBLs and MPALs. Nevertheless lineage 
assessment by means of CD79a alone would be hampered by its relatively low specificity, 
given the substantial proportion of CD79a co-expressing T-LBLs (12% in our series). 
Combination with a second B-cell marker is therefore mandatory. CD19 was found in our 
series to be a highly sensitive and specific B-cell marker. Pax5, a nuclear transcription factor 
involved in B-cell development 7, has not yet been recommended by the WHO for lineage 
determination in ALL. Our data confirm very recent observations that Pax5 is a highly specific 
and sensitive B-cell marker within the context of LBLs 15. It has nevertheless to be 
remembered that Pax5 has also been reported in rare non-hematopoetic neoplasms 
including tumors of the small round blue cell category 13, 23.    
 
We thus recommend screening all cases of LBL with CD3, MPO and CD79a and adding 
CD19 or Pax5 in CD79a positive cases to confirm or rule out B-cell lineage differentiation 
(figure 5). The use of CD20 in the lineage determination of precursor cell neoplasms is of 
limited value, since the sensitivity of this marker is low in B-LBL. Recently, CD22 staining 
protocols for FFPE specimens were published and it may prove to be another useful marker 
for confirming B-cell lineage 4. Because T-LBL cases may coexpress CD79a and CD10, 
CD10 might be useful as a second marker for confirming B-cell lineage only in CD19 strongly 
positive B-LBL, as recommended by the WHO classification 26, but if CD79a was applied, the 
second line B-cell marker should be either Pax5 or CD19 (Figure 5). It should also be noted 
that a precise quantification of the staining intensity of immune markers, as required for 
CD10 along with CD19 in the MPAL criteria of the WHO classification, cannot be reliably 
applied for immunohistochemistry.  
Although the criteria for lineage determination are now well defined by the WHO 
classification, immunophenotypical subtyping of stage of differentiation in B- and T-LBL is still 
based on the EGIL criteria and widely used in ALL 2. However, we faced several problems 
when we applied the proposed scheme for IHC staining on FFPE specimens. The subtyping 
of B-LBL is based on the expression of IgM and CD10. This can cause difficulties in cases 
where reliable IgM staining can not be achieved. Nevertheless, subtyping into the well 
established categories used for ALL, namely CD10-/IgM- pro-, CD10+/IgM- common- and 
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CD10+/IgM+ pre-B-LBL 2 was in our study possible in B-LBL when biopsy specimens of 
appropriate size are available It should be stressed that TdT positive pLBL very rarely 
express surface immunoglobulin light chains 10. 
The problems of subtyping according to the stage of differentiation are more pronounced in 
T-LBL, where it is necessary to differentiate between cytoplasmic and membranous CD3 
staining to distinguish pro- and pre-T-LBL from medullary/mature T-LBL 2. Although this is a 
standard procedure in flow cytometry, we did not find this distinction feasible for 
immunohistochemistry on FFPE specimens. Nevertheless, the cortical subtype could be 
reliably differentiated from noncortical T-LBL on the basis of CD1a expression, a distinction 
that has been found clinically relevant in ALL 6. Therefore we suggest using CD1a staining to 
identify cortical T-LBL in daily practice and lumping all further subtypes (pro/pre- and 
medullary/mature) together as noncortical T-LBL (Figure 5). It remains questionable whether 
the immunophenotypic subtypes of T-LBL defined by the EGIL criteria reflect a possible “cell 
of origin” accurately, since antigen expression in lymphomas may not precisely reflect the 
antigen expression pattern during during T-cell development 20. Being aware of the 
plasticicity in thymic developement it is generally considered that CD8+/CD4- single positive 
T-LBL should derive from relatively mature thymocytes, but we found CD34 expression, a 
marker indicating early T-cell precursors, in two of six CD8+/CD4- lymphomas analyzed 
(data not shown). Also, unexpectedly, CD34 and CD10 expression was seen in roughly the 
same percentage in cortical and noncortical T-LBLs (table 1). Genetic analysis of T-cell 
receptor gene rearrangement, flow cytometry data and results of molecular profiling can be 
expected to help identify new markers for distinguishing biologically relevant subtypes of T-
LBLs in the future. Moreover the possible clinical significance of CD34 expression in T-LBL 
should be evaluated in future studies 27. Further new diagnostic markers might be obtained 
from molecular profiling, although the published series are rather small 11, 18. 
Our study has several limitations. First of all, no genetic analysis was performed. Since the 
WHO classification uses several recurrent aberrations to delineate subtypes of B-ALL and 
MPAL 26 14, future studies on the cohort presented here will be valuable for studying these 
aberrations in LBL. Second, no clinical correlation could be performed, since the results of 
Euro-LB 02 trial have not been analyzed as yet. Our cohort will be the basis for future studies 
investigating prognostic markers that have been described in T-ALL for their applicability in 
T-LBL 28 and for understanding the clinical relevance of multi-lineage differentiation in 
neoplasms that present clinically not as ALL 1 but as lymphomas.  
 
We did not screen systematically for monocytic lineage differentiation, as recommended by 
the WHO. As discussed above, the WHO criteria were primarily designed for leukemias. 
Monocytic differentiation occurs frequently in AML, but may prove of lesser importance in 
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diseases presenting as lymphomas. Nevertheless, we identified an unexpectedly large 
number of precursor cell neoplasms with mixed lineage marker expression within our cohort 
of lymphomas that were diagnosed and included in the trial primarily as lymphoblastic 
lymphomas (7%). In these MPAL, myeloid/B-cell differentiation seemed to be the most 
frequent phenotype, a finding that is comparable to data published for leukemias (Xu et al., 
2009) (Bene, 2009). 5/10  cases tested  were also positive for CD34. Unfortunately, we do 
not have the cytogenetic data on these cases and therefore cannot exclude the possibility of 
myelosarcoma with t(8;21) in some of these cases.  The prognostic relevance of this finding 
is still uncertain. However, MPAL presenting as leukemia have been reported to show a very 
aggressive clinical course in adults 29 and also behaves more aggressiv than pALL in 
children 9. Our data indicate that systematic staining of precursor cell neoplasms for all three 
lineages (B-cell, T-cell and myeloid) should be performed in every case even if a lineage 
differentiation has already been assigned to the disease by a limited staining panel. The 
staining algorithm that we propose for pediatric LBL will help to limit immunohistochemical 
stainings and to identify MPAL (figure 5). In the very rare cases of UHN that we observed 
nonhematopoietic small round cell tumors should be carefully excluded and the staining 
panel for hematopoietic markers must be extended. It should be noted that CD99, a marker 
frequently used to identify Ewing’s sarcoma, may also be expressed in hematopoietic 
precursor cell neoplasms.  Expression of CD56 in absence of other haematopoietic markers 
in tumors of the posterior mediastinum neuroblastoma has to be considered in the differential 
diagnosis. 
 
 
Acknowledgement 
The authors would like to thank Frédérique Dijoud, Liliana Vila, Adriana Plesa and Marie-
Pierre Pagès for french cases review and Brigitte Ravis for french cases data management, 
Ulrike Meyer and Bettina Paul (NHL study center Giessen, Germany) for their excellent data 
management and Gabriele Buck for her technical assistance (NHL-BFM study center 
Giessen). We also thank Monika Hauberg, Olivera Batic, Charlotte Botz von Drathen and 
Christiane Mäder for their excellent technical support. This work was supported by the 
Kinder-Krebs-Initiative Buchholz, Holm-Seppensen and the national study groups for 
pediatric Non-Hodgkin Lymphoma of the participating pathologists. The NHL-BFM study 
center as the international coordination center of the trial was supported by the Deutsche 
Krebshilfe (grant No.107813). 
 
 
 12
  
References 
 
 1.  Bene MC. Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias! 
Haematologica. 2009;94:891-3. 
 2.  Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of 
acute leukemias. European Group for the Immunological Characterization of 
Leukemias (EGIL). Leukemia. 1995;9:1783-6. 
 3.  Bernd HW, Krokowski M, Feller AC, et al. Expression of terminal desoxynucleotidyl 
transferase in Merkel cell carcinomas. Histopathology. 2007;50:676-8. 
 4.  Browne P, Petrosyan K, Hernandez A, et al. The B-cell transcription factors BSAP, Oct-
2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the 
differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol. 2003;120:767-77. 
 5.  Buresh CJ, Oliai BR, Miller RT. Reactivity with TdT in Merkel cell carcinoma: a potential 
diagnostic pitfall. Am J Clin Pathol. 2008;129:894-8. 
 6.  Burkhardt B. Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two 
diseases? Br J Haematol. 2009. 
 7.  Cobaleda C, Schebesta A, Delogu A, et al. Pax5: the guardian of B cell identity and 
function. Nat Immunol. 2007;8:463-70. 
 8.  Feller AC, Parwaresch MR, Stein H, et al. Immunophenotyping of T-lymphoblastic 
lymphoma/leukemia: correlation with normal T-cell maturation. Leuk Res. 
1986;10:1025-31. 
 9.  Gerr H, Zimmermann M, Schrappe M, et al. Acute leukaemias of ambiguous lineage in 
children: characterization, prognosis and therapy recommendations. Br J Haematol. 
2010;149:84-92. 
 10.  Kansal R, Deeb G, Barcos M, et al. Precursor B lymphoblastic leukemia with surface 
light chain immunoglobulin restriction: a report of 15 patients. Am J Clin Pathol. 
2004;121:512-25. 
 11.  Martinez-Delgado B, Melendez B, Cuadros M, et al. Expression profiling of T-cell 
lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival 
related genes. Clin Cancer Res. 2004;10:4971-82. 
 13
 12.  McKenna RW, Asplund SL, Kroft SH. Immunophenotypic analysis of hematogones (B-
lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry. Leuk 
Lymphoma. 2004;45:277-85. 
 13.  Morgenstern DA, Hasan F, Gibson S, et al. PAX5 expression in nonhematopoietic 
tissues. Reappraisal of previous studies. Am J Clin Pathol. 2010;133:407-15. 
 14.  Mullighan CG, Downing JR. Genome-wide profiling of genetic alterations in acute 
lymphoblastic leukemia: recent insights and future directions. Leukemia. 2009;23:1209-
18. 
 15.  Nasr MR, Rosenthal N, Syrbu S. Expression profiling of transcription factors in B- or T-
acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 
immunostaining as pan-Pre-B-cell marker. Am J Clin Pathol. 2010;133:41-8. 
 16.  Perkins SL. Work-up and diagnosis of pediatric non-Hodgkin's lymphomas. Pediatr Dev 
Pathol. 2000;3:374-90. 
 17.  Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 
2004;350:1535-48. 
 18.  Raetz EA, Perkins SL, Bhojwani D, et al. Gene expression profiling reveals intrinsic 
differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic 
lymphoma. Pediatr Blood Cancer. 2006;47:130-40. 
 19.  Reiter A. Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology 
Am Soc Hematol Educ Program. 2007;285-96. 
 20.  Res P, Spits H. Developmental stages in the human thymus. Semin Immunol. 
1999;11:39-46. 
 21.  Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute 
lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: 
results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 
2000;95:3310-22. 
 22.  Smock KJ, Nelson M, Tripp SR, et al. Characterization of childhood precursor T-
lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a 
report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51:489-94. 
 23.  Sullivan LM, Atkins KA, LeGallo RD. PAX immunoreactivity identifies alveolar 
rhabdomyosarcoma. Am J Surg Pathol. 2009;33:775-80. 
 14
 24.  Sur M, AlArdati H, Ross C, et al. TdT expression in Merkel cell carcinoma: potential 
diagnostic pitfall with blastic hematological malignancies and expanded 
immunohistochemical analysis. Mod Pathol. 2007;20:1113-20. 
 25.  Swerdlow SH. Lymphomas: Epidemiologic, biologic, and pathogenetic features. In: 
Collins DC, Swerdlow SH, eds. pediatric hematopathology. New York, Edinburg, 
London, Philadelphia: Curchill Livingstone; 2001:199-210. 
 26.  Swerdlow SH, Campo E, Harris N, et al. WHO Classification of Tumors of the 
Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. 
 27.  van Grotel M, van den Heuvel-Eibrink MM, van Wering ER, et al. CD34 expression is 
associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Pediatr 
Blood Cancer. 2008;51:737-40. 
 28.  Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic 
profile at presentation and correlation with response to induction treatment in patients 
enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006;107:473-9. 
 29.  Xu XQ, Wang JM, Lu SQ, et al. Clinical and biological characteristics of adult 
biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and 
acute lymphoblastic leukemia: a case series of a Chinese population. Haematologica. 
2009;94:919-27. 
 
 
 15
 16
Figure Legends 
 
Figure 1: Examples of typical  and unusual morphology in LBL. Typical morphology LBL (A: 
H&E, B: TdT). Mediastinal biopsy specimen from a 3-year old male patient with T-LBL 
(noncortical subtype) showing an unusual immunoblastic morphology (C: H&E, D: TdT)). 
Lymph node biopsy specimen from a 6-year-old male with a B-LBL (common subtype) with 
unusual pleomorphic, centroblastic morphology (E: H&E, F: TdT). Original magnification 
400x, inserts 1000x.  
 
Figure 2: Immunohistochemistry for CD3 in two cases of T-LBL whose CD3 expression 
pattern had been determined by flow cytometry as cytoplasmic (A) and membranous (B). 
The corresponding immunohistochemical staining is shown.  
 
Figure 3: Mixed phenotype acute leukemia/lymphoma expressing CD3, CD5, CD19, CD79a 
but no Pax5. MPO in this case was negative. 
 
Figure 4: Requirements for assigning a lineage differentiation according to the WHO 
classification, which was designed primarily for flow cytometry (Swerdlow et al., 2008).  
 
Figure 5: Recommended staining algorithm for pediatric LBL for immunohistochemistry on 
FFPE specimens. 
 
